Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Research Grade Biosimilars

Anti-Human TREM-1 Reference Antibody (PY159, RUO) (HV219016)

Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Price(USD):
Spec:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.HV219016
Species reactivityHuman
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHuman
IsotypeIgG1-kappa
Clone IDPY159
Biological activity PY159 induceS signaling, upregulate monocyte activation markers, and stimulate proinflammatory cytokine production in human whole blood and dissociated primary tumor cells in vitro [3].
Expression system Mammalian cells
Clonality Monoclonal
Target TREM1, Triggering receptor expressed on monocytes 1, Triggering receptor expressed on myeloid cells 1, TREM-1, CD354
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q9NP99
Form Liquid
Storage buffer 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate NamesPY159
Background

Triggering receptor expressed on myeloid cells 1 (CD354/TREM1) is a ~26 kDa protein. Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12. In turn, initiates a SYK-mediated cascade of tyrosine phosphorylation, activating multiple downstream mediators such as BTK, MAPK1, MAPK3 or phospholipase C-gamma. This cascade promotes the neutrophil- and macrophage-mediated release of pro-inflammatory cytokines and/or chemokines, as well as their migration and thereby amplifies inflammatory responses that are triggered by bacterial and fungal infections. By also promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptor (TLR) and NOD-like receptor engagement, plays a major role in the pathophysiology of acute and chronic inflammatory diseases of different etiologies including septic shock and atherosclerosis.

1. Bouchon, A. et al. (2000) Journal of immunology (Baltimore, Md. : 1950) 164, 4991-5. PMID: 10799849
2. Arts, RJ. et al. (2011) European cytokine network 22, 11-4. PMID: 21393102
3. El Mezayen, R. et al. (2007) Immunology letters 111, 36-44. PMID: 17568691
4. Read, CB. et al. (2015) Journal of immunology (Baltimore, Md. : 1950) 194, 1417-21. PMID: 25595774
5. Carrasco, K. et al. (2019) Cellular & molecular immunology 16, 460-472. PMID: 29568119
6. Radaev, S. et al. (2003) Structure (London, England : 1993) 11, 1527-35. PMID: 14656437
7. Ormsby, T. et al. (2011) Blood 118, 936-45. PMID: 21659545
8. Fortin, CF. et al. (2007) International immunology 19, 41-50. PMID: 17098818
9. Bouchon, A. et al. (2001) Nature 410, 1103-7. PMID: 11323674
References 1. Oladapo Yeku, et al. Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer. December 2023. Immuno-Oncology Technology. [HV219016]
2. Yeku OO, et al. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13(3):e010959. Published 2025 Mar 13. [HV219016]
3. Nadine Jahchan, et al. Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors. Journal for ImmunoTherapy of Cancer. November 2021. 9(Suppl 3):A900-A900 [HV219016]
4. Ira Seth Winer, et al. A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1). J Clin Oncol 41, 2523-2523(2023). View More [HV219016]
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    Bioactivity

    Detects Human CD354/TREM1 in indirect ELISAs.

  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD354/TREM1 (PY159).

  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    Western blot

    Western blot analysis was performed using anti-CD354/TREM1 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human CD354/TREM1 (Catalog No: HV219012), 50ng
    Lane 2: recombinant human CD354/TREM1 (Catalog No: HV219012), 30ng

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list